Curtis Lockshin
Chief Tech/Sci/R&D Officer at XENETIC BIOSCIENCES, INC.
Net worth: 2 176 $ as of 2024-03-30
Profile
Dr. Curtis A.
Lockshin is a Chief Scientific Officer at Xenetic Biosciences, Inc. and an Independent Director at Phio Pharmaceuticals Corp.
He is on the Board of Directors at Phio Pharmaceuticals Corp.
and Ruth K.
Broad Biomedical Research Foundation, Inc. Dr. Lockshin was previously employed as a Chief Technical Officer by VBI Vaccines, Inc., a Chief Technical Officer by SciVac Ltd., a Chief Executive Officer & Director by SciVac Therapeutics, Inc., a Vice President-Research & Operations by Xenetic Biosciences (UK) Ltd., a President & Chief Executive Officer by Guardum Pharmaceuticals LLC, a Vice President-Research & Development Initiatives by OPKO Health, Inc., an Independent Non-Executive Director by Chromadex Corp., an Independent Director by Sorrento Therapeutics, Inc., a Director-Discovery Biology by Beyond Genomics, Inc., and a Director-Discovery Biology & Informatics by Sunovion Pharmaceuticals, Inc. He also served on the board at Winston Pharmaceuticals, Inc., Quikbyte Software, Inc., clickNsettle.com, Inc., Tiger X Medical, Inc., Getting Ready Corp.
and Orthodontix, Inc. He received his undergraduate degree from Massachusetts Institute of Technology and a doctorate degree from Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-14 | 3,200 ( 0.13% ) | 2 176 $ | 2024-03-30 | |
| 2023-12-10 | 0 ( -.--% ) | - $ | 2024-03-30 |
Curtis Lockshin active positions
| Companies | Position | Start |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Director/Board Member | 2013-04-17 |
| XENETIC BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2017-01-03 |
| Ruth K. Broad Biomedical Research Foundation, Inc. | Director/Board Member | 2004-03-31 |
Former positions of Curtis Lockshin
| Companies | Position | End |
|---|---|---|
Xenetic Biosciences (UK) Ltd.
 Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Chief Operating Officer | 2016-12-31 |
| VBI VACCINES INC. | Chief Tech/Sci/R&D Officer | 2016-12-21 |
| SciVac Therapeutics, Inc. | Chief Executive Officer | 2016-06-30 |
| CHROMADEX CORPORATION | Director/Board Member | 2014-01-02 |
| OPKO HEALTH, INC. | Chief Tech/Sci/R&D Officer | 2013-01-31 |
Training of Curtis Lockshin
| Massachusetts Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 8 |
|---|---|
| BG MEDICINE, INC. | Health Technology |
| OPKO HEALTH, INC. | Health Services |
| CHROMADEX CORPORATION | Health Technology |
| WINSTON PHARMACEUTICALS, INC. | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| PHIO PHARMACEUTICALS CORP. | Health Technology |
| XENETIC BIOSCIENCES, INC. | Health Technology |
| VBI VACCINES INC. | Health Technology |
| Private companies | 11 |
|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
clickNsettle.com, Inc.
 clickNsettle.com, Inc. Internet Software/ServicesTechnology Services The Company's principal activity is to seek a new operating business or enter into a merger transaction. Previously the Company provided arbitration and mediation services, also known as alternative dispute resolution services (ADR) and related electronic oversight applications. In addition, the Company offered advisory opinions, mock jury trials and other specialized dispute resolution programs depending on the parties' particular needs. Currently the Company does not operate any business. | Technology Services |
| Orthodontix, Inc. | Finance |
Getting Ready Corp.
 Getting Ready Corp. Financial ConglomeratesFinance The Company intends to open Mother Supercare Centers in target areas across the United States. The Mother Supercare Centers will offer prenatal, childbirth, postpartum and parenting services to women and their families. These services will be provided through education, counseling, support services and products for women and infants that promote a healthy pregnancy, birth, postpartum and early parenting period. The Group is a development Stage Company. | Finance |
Quikbyte Software, Inc.
 Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | Finance |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Tiger X Medical, Inc.
 Tiger X Medical, Inc. Medical SpecialtiesHealth Technology Tiger X Medical, Inc. engages in the collection and management of royalty income earned in connection with the Asset Purchase Agreement with Arthrex, Inc. It continue to advance and promote its former knee product lines through participation in mobile teaching labs, seminars, and live surgery. Its also evaluates future investment opportunities and uses for its cash. The company was founded by Andrew A. Brooks on April 6, 2007 and is headquartered in Los Angeles, CA. | Health Technology |
| Ruth K. Broad Biomedical Research Foundation, Inc. | |
Guardum Pharmaceuticals LLC
 Guardum Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Pharmsynthez PJSC, Guardum Pharmaceuticals LLC produces pharmaceutical preparations. The private company is based in Miami, FL. Guardum Pharmaceuticals was acquired by Pharmsynthez PJSC on April 18, 2013. | Health Technology |
SciVac Ltd.
 SciVac Ltd. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., SciVac Ltd. is an Israeli company that develops and markets biological products for human healthcare. The private company is based in Rehovot, Israel. SciVac was acquired by Levon Resources Ltd. on July 09, 2015 for $73.16 million. | Health Technology |
| SciVac Therapeutics, Inc. | Health Technology |
- Stock Market
- Insiders
- Curtis Lockshin
